Skip to main content
SpringerLink
Log in

Alzheimer's peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome

  • Published:
Documenta Ophthalmologica Aims and scope Submit manuscript

Abstract

The occurrence of inflammation with accompanying amyloid formation in pseudoexfoliation syndrome (PEX) resembles other inflammation-associated amyloidoses such as Alzheimer's disease (AD). To test whether the same proteins can be identified in PEX as in AD, we qualitatively analysed for Alzheimer's peptide (Aβ1-42) and the proteinase inhibitors α1-antichymotrypsin (ACT) and α1-antitrypsin (AAT) in the aqueous humor of patients with and without PEX material. Ninety aqueous humor samples were collected from patients in the age group between 46 and 95 during cataract surgery. Protein profiles in samples were analysed by electrophoresis followed by Western blotting. Blots were developed using specific antibodies against Aβ1-42, AAT and ACT and peroxidase-conjugated IgG as a second antibody. At least one of the analysed proteins was found in 68.8% of 90 cases studied. Aβ1-42 peptide was found in 22.2% of all cases, among them in seven cases with PEX (total n=16) and in four with glaucoma (total n=10). ACT and AAT were detected in 17.8 and 28.9% of all cases, respectively. In addition, female patients had significantly higher frequencies of detected ACT and AAT, compared to males. Aβ1-42, ACT and AAT were also found in 17.6, 14.7 and 23.5% of the control (non-XF and non-glaucoma) samples (n=68). Alzheimer's peptide is present in the aqueous humor of patients with PEX and glaucoma suggesting that these diseases may share common features in the biochemistry and etiologies with AD. The presence of Aβ and inflammation-associated proteins in aqueous from cataract cases without detectable PEX raises the possibility that these proteins may reflect early amyloid-related changes in the eye.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cristini G. The rationale of ocular hypertension in Glaucoma, the common basis for hypertension and nervous atrophy. XVI Concilium Ophthal. London 1951: 865–71.

    Google Scholar 

  2. Khalil AK, Kubota T, Tawara A, Inomata H. Early changes in iris blood vessels in exfoliation syndrome. Curr Eye Res 1998; 17: 1124–34.

    Google Scholar 

  3. Cristini G, Consolani A, Lazzari F. Ocular hypertension in primary glaucoma: a new hypotetis. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1980; 213: 283–90.

    Google Scholar 

  4. Ducker HJ. Pathogenesis of the pseudoexfoliation syndrome. Fortschr Ophthalmol 1982; 79: 142–43.

    Google Scholar 

  5. Vesti E, Kivel T. Exfoliation syndrome and exfoliation glaucoma. Prog Retin Eye Res 2000; 19: 345–68.

    Google Scholar 

  6. Brooks A, Gillies WE. Fluorescein angiography and fluorometry of the iris in pseudoexfoliation of the lens capsule. Br J Ophthalmol 1983; 67: 249–54.

    Google Scholar 

  7. Kuchle M, Nguyen NX, Hannappel E, Naumann GO. The blood–aqueous barrier in eyes with pseudoexfloiaton syndrome. Ophthalmic Res 1995; 27: 136–42.

    Google Scholar 

  8. Ringvold A. Pseudo-exfoliation material-an amyloid like substance. Exp Eye Res 1973; 17: 289–99.

    Google Scholar 

  9. Ringvold A, Husby G, Pettersen S. Electrophoretic study of proteins associated with pseudo-exfoliation syndrome. Acta Ophthal 1989; 67: 724–26.

    Google Scholar 

  10. Morrison BM, Hof PR, Morrison JH. Determinants of neuronal vulnerability in neurodegenerative diseases. Ann Neurol 1998; 44: 32–44.

    Google Scholar 

  11. Naumann GO, Schlotzer-Schrehardt U, Kuchle M. Pseudoexxfoliation syndrome for the comprehensive ophthalmologist. Intraocular and systemic manifestations. Ophthalmology 1998; 105: 951–68.

    Google Scholar 

  12. Koliakos G, Konstas GP, Triantos A, Ritch R. Increased growth factor activity in the aqueous humour of patients with exfoliation syndrome. Graefes Arch Clin Exp Ophthalmol 2000; 238: 491–95.

    Google Scholar 

  13. Sawa M, Tsurimaki Y, Tsuru T, Shimizu H. New quantitative method to determine protein concentration and cell number in aqueous in vivo. Jpn J Ophthalmol 1988; 32: 132–42.

    Google Scholar 

  14. Damji KF, Bains HS, Stefansson E, Loftsdottir M, Sverrisson T, Thorgeirsson E, Jonasson F, Gottfredsdottir M, Allingham RR In psedoexfoliation syndrome inherited? A review of genitic and nongenitc factors and a new observation. Ophthalmic Genet 1998; 19: 175–85.

    Google Scholar 

  15. Lowe J, Landon M, Pike I, Spendlove I, McDermott H, Mayer RJ. Dementia with beta-amyloid deposition: involvement of alpha B-crystallin supports two main diseases. Lancet 1990; 336: 515–16.

    Google Scholar 

  16. Vickers JC. The cellular mechanism underlying neuronal degeneration in glaucoma: parallels with Alzheimer's disease. Aust N Z J Ophthalmol 1997; 25: 105–9.

    Google Scholar 

  17. Loffler KU, Edward DP, Tso MO. Immunoreactivity against tau, amyloid precursor protein, and beta amyloid in the human retina. Invest Ophthamol Vis Sci 1995; 36: 24–31.

    Google Scholar 

  18. Cooper NR, Bradt BM, O'Barr S, Yu JX. Focal inflammation in the brain: role in Alzheimer's disease. Immunol Res 2000; 21: 159–65.

    Google Scholar 

  19. Emmerling MR, Morganti-Kossmann MC, Kossmann T, Stahel PF, Watson MD, Evans LM, Mehta PD, Spiegel K, Kuo YM, Roher AE, Raby CA. Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury. Ann N Y Acad Sci 2000; 903: 118–22.

    Google Scholar 

  20. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 2000; 130: 184–208.

    Google Scholar 

  21. Tomiyama T, Corder EH, Mori H. Molecular pathogenesis of apolipoprotein E-mediated amyloidosis in late-onset Alzheimer's disease. Cell Mol Life Sci. 1999; 56: 268–79.

    Google Scholar 

  22. Nilsson LN, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM, Potter H α-1-Antichymotrypsin promotes β-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J Neurosci 2000; 21: 1444–51.

    Google Scholar 

  23. Frederikese PH, Ziegler SJ Jr, Fransworth PN, Carper DA. Prion protein expression in mammalian lenses. Curr Eyes Res 2000; 20: 137–43.

    Google Scholar 

  24. Frederikse PH, Garland D, Ziegler SJ Jr, Piatigorsky J. Oxidative stress in increases produktion on β-Amyloid precursor protein and β-Amyloid (Aβ) in mammalian lenses an Aβ has toxic effects on lens Epithelial cells. Am Soc Biochem Molec Biol Inc 1996; 271: 10169–74.

    Google Scholar 

  25. Frederikse PH, Zigler JS Jr. Presenilin expression in the ocular lens. Curr Eye Res 1998; 17: 947–52.

    Google Scholar 

  26. Abraham CR. The role of the acute-phase protein α1-antichymotrypsin in brain dysfunction and injury. Res Immunol 1992; 143: 631–36.

    Google Scholar 

  27. Janciauskiene S, Rubin H, Lukacs CM, Wright HT. Alzheimer's peptide A?1?42 binds to two beta-sheets of ?1-antichymotrypsin and transforms it from inhibitor to substrate. J Biol Chem 1998; 273: 28360–64.

    Google Scholar 

  28. Janciauskiene S, Wright HT. Inflammation, antichymotrypsin, and lipid metabolism: autogenic etiology of Alzheimer's disease. Bioessays 1998; 20: 1039–46.

    Google Scholar 

  29. Fraser PE, Nguyen JT, McLachlan DR, Abraham CR, Kirschner DA. Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem 1993; 61:298–305.

    Google Scholar 

  30. Licastro F, Sirri V, Trere D, Davis LJ. Monomeric and polymeric forms of alpha-1 antichymotrypsin in sera from patients with probable late onset Alzheimer's disease. Dement Geriatr Cogn Disord 1997; 8: 337–42.

    Google Scholar 

  31. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655–709.

    Google Scholar 

  32. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY Reference distributions for the positive acute phase serum proteins, alpha1-acid glycoprotein (orosomucoid), alpha1-antitrypsin, and haptoglobin: a practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Anal 2000; 14: 284–92.

    Google Scholar 

  33. Boskovic G, Twining SS. Local control of alpha1-proteinase inhibitor levels: regulation of alpha1-proteinase inhibitor in the human cornea by growth factors and cytokines. Biochim Biophys Acta 1998; 1403: 37–46.

    Google Scholar 

  34. Harding JJ. Alzheimer's disease and cataract: common threads. Alzheimer Dis Assoc Disord 1993; 7: 55–6.

    Google Scholar 

  35. Harding JJ. Cataract, Alzheimer's disease, and other conformational diseases. Curr Opin Ophthalmol 1998; 9: 10–13.

    Google Scholar 

  36. Xu J, Chen S, Ahmed SH, Chen H, Ku G, Goldberg MP, Hsu CY Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 2001; 21: RC118.

    Google Scholar 

  37. Sutton ET, Thomas, Bryant MW, Landon CS, Newton CA, Rhodin JA. Amyloid-beta peptide induced inflammatory reaction is mediated by the cytokines tumor necrosis factor and interleukin-1. J Submicrose Cytol Pathol 1999; 313: 13–23F.

    Google Scholar 

  38. Goldsbury CS, Wirtz S, Muller SA, Sunderji S, Wicki P, Aebi U, Frey P. Studies on the in vitro assembly of a beta 1–40: implications for the search for a beta fibril formation inhibitors. J Struct Biol 2000; 130: 217–31.

    Google Scholar 

  39. Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-Trafit B, Naslund J, Richards G, Huber W, Dobeli H, Nordstedt C. Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. J Biol Chem 1999; 274: 15990–5.

    Google Scholar 

  40. Findeis MA. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim Biophys Acta 2000; 1502: 76–84.

    Google Scholar 

  41. Ritch R. Exfoliation syndrome and occludable angles. Trans Am Ophthalmol Soc 1994; 92: 845–944.

    Google Scholar 

  42. Lindblom B, Thorburn W. Functional damage at diagnosis of primary open angle glaucoma. Acta Ophthalmol (Copenhagen) 1984; 62: 223–9.

    Google Scholar 

  43. Hu DN, Ritch R. Hepatocyte growth factor is increased in the aqueous humor of glaucomatous eyes. J Glaucoma 2001; 10: 152–7.

    Google Scholar 

  44. Panayotou G, End P, Aumailley M, Timpl R, Engel J. Domains of laminin with growth-factor activity. Cell 1989; 56: 93–101.

    Google Scholar 

  45. Villa A, Latasa MJ, Pascual A. Nerve growth factor modulates the expression and secretion of beta-amyloid precursor protein through different mechanisms in PC12 cells. J Neurochem 2001; 77:1077–84.

    Google Scholar 

  46. Apelt J, Schliebs R. Beta-amyloid-induced glial expression of both pro-and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res 2001; 894: 21–30.

    Google Scholar 

  47. Strohmeyer R, Rogers J. Molecular and cellular mediators of Alzheimer's disease inflammation. J Alzheimer's Dis 2001; 3: 131–57.

    Google Scholar 

  48. Chung HS, Harris A, Evans DW, Kagemann L, Garzozi HJ, Martin B. Vascular aspects in the pathophysiology of glaucomatous optic neurophaty. Surv Ophthalmol 1999; 43(Suppl): S43–50.

    Google Scholar 

  49. Gooptu B, Hazes B, Chang WS, Dafforn TR, Carrell RW, Read RJ, Lomas DA. Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational disease. Proc Natl Acad Sci USA 2000; 97: 67–72.

    Google Scholar 

  50. Janciauskiene S, Eriksson S, Wright HT. A specific structural interaction of Alzheimer's peptide A beta 1-42 with alpha 1-antichymotrypsin. Nat Struct Biol 1996; 3: 668–71.

    Google Scholar 

  51. Saito H, Shultz LD, Sinha M, Papaconstantinou J. Induction of the alpha(1)-antichymotrypsin gene in the brain associated with TGF-beta1 deficiency or systemic administration of endotoxin. Biochem Biophys Res Commun 1999; 263: 270–5.

    Google Scholar 

  52. Ritch R. Exfoliation syndrome. Curr Opin Ophthalmol 2001; 12: 124–30.

    Google Scholar 

  53. Stefan C, Cucea R, Popescu A, Stoenescu D. Cataract and exfoliative syndrome. Oftalmologia 1998; 42: 33–6.

    Google Scholar 

  54. Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 2001; 42: 1787–94.

    Google Scholar 

  55. Linner E, Popovic V, Gottfries CG, Jonsson M, Sjogren M, Wallin A. The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type. Acta Ophthalmol Scand 2001; 79: 283–5.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of, Sweden

    Sabina Janciauskiene

  2. Medicine and Ophthalmology, University Hospital Malmö, S-20502, Malmö, Sweden

    Torsten Krakau

Authors
  1. Sabina Janciauskiene
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Torsten Krakau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Janciauskiene, S., Krakau, T. Alzheimer's peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome. Doc Ophthalmol 106, 215–223 (2003). https://doi.org/10.1023/A:1022949121078

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022949121078

Search

Navigation